

A Review of Plants Used in the Treatment of Liver Disease: Part 1

by Scott Luper, N.D.

Abstract

Botanicals have been used traditionally by herbalists and indigenous healers worldwide for the prevention and treatment of liver disease. Clinical research in this century has confirmed the efficacy of several plants in the treatment of liver disease. Basic scientific research has uncovered the mechanisms by which some plants afford their therapeutic effects. *Silybum marianum* (milk thistle) has been shown to have clinical applications in the treatment of toxic hepatitis, fatty liver, cirrhosis, ischemic injury, radiation toxicity, and viral hepatitis via its antioxidative, anti-lipid peroxidative, antifibrotic, anti-inflammatory, immunomodulating, and liver regenerating effects. *Picrorhiza kurroa*, though less well researched than Silybum, appears to have similar applications and mechanisms of action. When compared with Silybum, the hepatoprotective effect of Picrorhiza was found to be similar, or in many cases superior, to the effect of Silybum. (*Altern Med Rev* 1998;3(6):410-421)

Introduction

Treatment options for common liver diseases such as cirrhosis, fatty liver, and chronic hepatitis are problematic. The effectiveness of treatments such as interferon, colchicine, penicillamine, and corticosteroids are inconsistent at best and the incidence of side-effects profound. All too often the treatment is worse than the disease. Conservative physicians often counsel watchful waiting for many of their patients, waiting in fact for the time when the disease has progressed to the point that warrants the use of heroic measures. Physicians and patients are in need of effective therapeutic agents with a low incidence of side-effects. Plants potentially constitute such a group.

In recent years many researchers have examined the effects of plants used traditionally by indigenous healers and herbalists to support liver function and treat diseases of the liver. In most cases, research has confirmed traditional experience and wisdom by discovering the mechanisms and modes of action of these plants as well as reaffirming the therapeutic effectiveness of certain plants or plant extracts in clinical studies.

Several hundred plants have been examined for use in a wide variety of liver disorders. Just a handful have been fairly well researched. The latter category of plants include: *Silybum marianum* (milk thistle), *Picrorhiza kurroa* (kutkin), *Curcuma longa* (turmeric), *Camellia sinensis* (green tea), *Chelidonium majus* (greater celandine), *Glycyrrhiza glabra* (licorice), and *Allium*

Scott Luper, N.D. is Chair of Diagnostics at Southwest College of Naturopathic Medicine where he teaches and supervises clinical education. Correspondence address: 2140 East Broadway Rd, Tempe, AZ 85282, e-mail:lupers@cwix.com

sativa (garlic). This review will be divided into two parts. *Silybum marianum* and *Picrorhiza kurroa*, will be reviewed in Part One. *Curcuma longa*, *Camellia sinensis*, *Chelidonium majus*, *Glycyrrhiza glabra*, and *Allium sativa* will be reviewed in Part Two.

Silybum marianum (milk thistle)

Silybum marianum is currently the most well researched plant in the treatment of liver disease (with over 450 published peer review papers). The genus *Silybum* is a member of the daisy family (Compositae). The plant itself is a stout thistle, growing one to three meters tall in rocky soils, with large purple flowering heads (Figure 1). The leaves are characterized by distinct white "milky" veins that give the plant its common name.

History, Early Authors

Silybum is cited as one of the oldest known herbal medicines. Dioscorus first described the plant. In Roman times, Pliny the Elder (A.D. 77), a noted naturalist, described the medicinal uses of milk thistle, indicating it was "excellent for carrying off bile."¹ Culpeper (1650) wrote of its effectiveness in removing obstructions of the liver and spleen.² But it has been relatively recent clinical research, especially in Germany, which has brought the use of *Silybum* to prominence

in the treatment of chronic or acute liver disease, as well as protecting the liver against toxicity.

Active Constituents

The active constituents of milk thistle are flavonolignans including silybin, silydianin, and silychristine, collectively known as silymarin. Silybin (Figure 2) is the component with the greatest degree of biological activity, and milk thistle extracts are usually standardized to contain 70-80 percent silybin. Silymarin is found in the entire plant but is concentrated in the fruit and seeds. *Silybum* seeds also contain betaine (a proven hepatoprotector) and essential fatty acids, which may contribute to silymarin's anti-inflammatory effect.

Figure 1. Milk Thistle



Pharmacokinetics

Silymarin is not water soluble and so cannot be taken as a tea. It is typically administered as an encapsulated standardized extract. The absorption with oral administration is rather low with only two to three percent of the silybin recovered in 24 hours from rat bile.^{3,4} The peak plasma levels after an oral dose are achieved in four to six hours in both animals and humans.³⁻⁵ Silymarin is cleared from the body predominantly via the bile and to a lesser extent the kidney. The clearance half-life is six to eight hours.⁵

Figure 2. Silybin



one series of 18 patients treated with silymarin, all patients survived except one particularly high-dose suicide. The authors concluded, "Administration of silymarin even up to 48 hours after mushroom ingestion appears to be an effective measure to prevent severe liver damage in *Amanita phalloides* poisoning."⁸ In a 1995 study of

Clinical Indications

Mushroom Poisoning: The most remarkable use of silymarin is in the treatment of *Amanita* mushroom poisoning. The *Amanita* genus is widespread in Europe and North America, and several species are considered choice by mushroom collectors. Unfortunately, the genus also contains several of the most toxic mushrooms in existence. *Amanita* mushrooms possess two extremely powerful hepatotoxins, amanitin and phalloidin (the LD50 of amanitin is 0.1 mg/kg body weight). Historically, the accidental ingestion of mushrooms containing these toxins results in about 60 cases of poisoning per year in the United States and Europe, with a mortality rate of about 30 percent.⁶

In mice, silymarin was 100 percent effective in preventing liver toxicity if given before or up to ten minutes after *Amanita* toxin poisoning. Severe liver damage (and death) was avoided if silymarin was administered within 24 hours.⁷ In a study with dogs (who model human *Amanita* poisoning quite well), none of the dogs died when given silymarin 5-24 hours after ingesting an LD50 dose of *Amanita phalloides* (85 mg/kg). In comparison, untreated dogs experienced a mortality rate of 33 percent. Liver enzyme studies and liver biopsies in the controls and treated dogs demonstrated a significant hepatoprotective effect for the silymarin.⁶

The hepatoprotective effects of silymarin in humans after ingestion of *Amanita* toxins have been repeatedly demonstrated. In

41 mushroom poisoning victims, none died in the group which included silymarin in the treatment regimen.⁹

A 1996 report made the case that silymarin may be useful even three days post toxification. A family of four poisoned by *Amanita* mushrooms was admitted to the hospital with severe liver damage. Although all were treated with standard therapy, there was a worsening of the clinical picture until the third day, when it was decided to add silybin dihemisuccinate by intravenous route to the therapy. After the beginning of silybin administration the patients showed a favorable course with a rapid resolution of the clinical picture, although the prognosis appeared severe on the basis of hepatochemical examination results.¹⁰

A particularly dramatic case of a very severe accidental poisoning in a seven-year-old girl resulted in her entering a hepatic coma. The authors reported the girl's survival was due in large part to treatment with silymarin in combination with high doses of G-penicillin.¹¹

General Hepatoprotective: Many studies have demonstrated the beneficial hepatoprotective effects of treatment with silymarin. In a Finnish military hospital study on consecutive patients with elevated serum liver enzymes (mostly due to ethanol ingestion), 420 mg/day silymarin was found to significantly lower liver enzymes – aspartate aminotransferase (AST), alanine aminotransferase (ALT) – after four weeks. Histologic examination of liver biopsies also

demonstrated a statistically significant improvement.¹²

In an Italian study of 20 patients with chronic active hepatitis, 240 mg/day of silybin-phosphatidylcholine complex for only seven days was found to significantly lower serum liver enzymes – AST, ALT, gamma-glutamyl transferase (GGT), alkaline phosphatase, and total bilirubin.¹³

In a Hungarian study of 36 patients with chronic alcoholic liver disease, 420 mg/day of silymarin resulted in a normalization in serum liver enzymes (AST, ALT, GGT), total bilirubin, and an improvement in the histological examination of liver biopsies after six months of treatment. In addition, procollagen III peptides (a marker of active fibrosis) were found to be significantly decreased in the treatment group.¹⁴

In an Austrian study involving 170 patients with liver cirrhosis, 420 mg/day of silymarin for an average of 41 months resulted in a significant improvement in survival (58% in silymarin-treated patients and 39% in the placebo group ($P = 0.036$)). No side-effects of silymarin were noted in this study¹⁵ or in others cited above.

Not every study found a beneficial effect of silymarin administration. In a French study on 116 patients with histologically proven alcoholic hepatitis, 420 mg/day of silymarin for three months was not found to significantly alter the course of the disease. Both the treated and the placebo groups had similar rates of abstinence (46%), and significant improvement in the score of alcoholic hepatitis and serum amino transferase activity, irrespective of treatment with silymarin or placebo. Four patients died of hepatic failure during the trial, one in the treatment group and three in the placebo group (not statistically significant). As usual, no side-effects were noted.¹⁶

It is interesting to note that while silymarin has been shown to have a profound hepatoprotective effect on chronic exposure

to ethanol, it has no direct effect on ethanol metabolism. When studied, silybin had no effect on reducing blood ethanol levels or the rate at which ethanol is removed from the body.¹⁷

Mechanism of Action

Silymarin has been reported to protect liver cells from a wide variety of toxins, including acetaminophen, ethanol, carbon tetrachloride, and D-galactosamine.¹⁸⁻²³ Silymarin has also been found to protect liver cells from ischemic injury,²⁴ radiation,²⁵ iron toxicity,²⁶ and viral hepatitis.²⁷

The mechanisms which provide silymarin's hepatoprotective effects are many and varied, and include antioxidation,^{21,26,28} anti-lipid peroxidation,^{19,28,29} enhanced detoxification,³⁰⁻³² and protection against glutathione depletion.^{33,23} Silymarin has been found to inhibit the formation of leukotrienes from polyunsaturated fatty acids in the liver, via its inhibition of the enzyme lipoxygenase. These leukotrienes are known to be some of the most damaging chemicals found in man.³⁴

Studies also demonstrated that silymarin increased hepatocyte protein synthesis,^{35,36} decreased the activity of tumor promoters,³⁷ stabilized mast cells,³⁸ modulated immune functions,^{39,40} and was anti-inflammatory⁴¹⁻⁴³ and antifibrotic.⁴⁴⁻⁴⁶

Stimulation of Liver Regeneration: One of the mechanisms to explain the ability of silymarin to stimulate the regeneration of hepatic tissue is the increase in protein synthesis in damaged livers. In both *in vivo* and *in vitro* experiments, significant increases in the formation of ribosomes and DNA synthesis were measured in addition to the increase in protein synthesis. Interestingly, the increased protein synthesis was only measured in damaged livers (partial hepatectomy), not in controls.³⁵ The mechanism of increased protein synthesis is currently not known but some authors speculate silymarin imitates a

physiologic regulator, so the silybin fits into a specific binding site on the polymerase, thus stimulating ribosome formation.³⁶

The potential for stimulation of protein synthesis by silymarin was investigated in malignant liver tissue, and no increases in protein synthesis, ribosome formation, or DNA synthesis were found in malignant cell lines.³⁵

Anti-inflammatory Effects: The mainstays of the current medical management of nonviral chronic hepatitis are immunosuppressive/anti-inflammatory medications (e.g., prednisone, azathioprine). While use of these drugs may be lifesaving, long-term use may result in debilitating, life-threatening side-effects. Doctors and patients need safe and effective alternative anti-inflammatory medications. Botanical anti-inflammatories may constitute such a group.

Silymarin has been shown to have significant anti-inflammatory effects on hepatic tissue. Several studies have demonstrated a variety of anti-inflammatory effects, including mast cell stabilization,³⁸ inhibition of neutrophil migration,⁴⁷ Kupffer cell inhibition,⁴³ strong inhibition of leukotriene synthesis, and prostaglandin formation.⁴¹⁻⁴³

Antifibrotic Effects: Hepatic stellate cells play a central pathogenic role in liver fibrogenesis. In response to some fibrotic influences (e.g., chronic ethanol exposure, carbon tetrachloride, etc.), they proliferate and transform into myofibroblasts, which are responsible for the deposition of collagen fibers in the liver. One recent study investigated the effect of silybin on the transformation of hepatic stellate cells into myofibroblasts. Silybin [10^{-4} mol/l concentration] was found to reduce the proliferation of freshly isolated rat hepatic stellate cells by about 75 percent. It also reduced the conversion of stellate cells into myofibroblasts and down-regulated the gene expression of extracellular matrix components necessary for fibrosis.⁴⁴

Silymarin has been shown to slow or reverse liver fibrosis in animals. Rats were subjected to a complete bile duct occlusion which consistently causes progressive liver fibrosis without inflammation. Silymarin was able to reduce the fibrosis by 30-35 percent in comparison with controls (50 mg/kg/day, human dose = 3500 mg/day). Silymarin worked equally if used continuously for six weeks after the bile duct occlusion or only for the final two weeks. Dosage at 25 mg/kg/day (human dose = 1750 mg/day) was not found to be effective.⁴⁵

Colchicine is currently used to inhibit fibrosis of the liver. It functions as an antifibrotic and anti-inflammatory by inhibiting macrophage stimulation of fibrosis. Unfortunately, colchicine has a narrow, unpredictable therapeutic window, and serious, life-threatening side-effects, including liver failure, renal failure, myocardial injury, severe gastrointestinal damage, shock, and death. In a rat study using carbon tetrachloride-induced liver fibrosis, silymarin was found to be very similar to colchicine for the prevention of chronic liver fibrosis, but without any side-effects.⁴⁶

Inhibition of P450: Paradoxically, silymarin may have an inhibitory effect on the cytochrome P450 (Phase I) detoxification system. In a recently published animal study, silybin was found to inhibit several specific induced P450 enzymes in mice.³⁰ Other researchers have noted the lack of stimulatory effect on the P450 detoxification system.^{29,31} This effect may explain some of the hepatoprotective effects of silymarin, especially against Amanita poisoning. Amanitin toxin becomes deadly to hepatocytes only after it becomes bioactivated by the P450 system. The inhibition of the bioactivation of amanitin could reduce its toxic effects. In addition, silymarin and other antioxidants afford some protection against the free radicals generated by P450 enzymes.⁴⁸

Enhanced Glucuronidation: Glucuronidation is an important Phase II liver detoxification pathway. More toxins are removed from the body via glucuronidation than any other single detoxification pathway.⁴⁸ Glucuronic acid is conjugated with toxins to facilitate their elimination from the body via the bile. In addition, many other substances, including estrogen, are removed from the body via glucuronidation. Unfortunately, some intestinal bacteria (mostly pathogenic) possess an enzyme, beta-glucuronidase, that enables them to remove glucuronic acid from the conjugated substance and use it as an energy source. This allows the original molecule to be reabsorbed through the GI mucosa, thus re-exposing the person to the removed substance. Silymarin was found to inhibit the activity of beta-glucuronidase 53 percent in healthy humans and in one patient with colon cancer.³²

Immunomodulation: Researchers have investigated the immunomodulatory effects of silymarin on the diseased liver. A pair of Hungarian studies demonstrated a positive effect of silymarin on immune function. The first study looked at patients with histologically proven chronic alcoholic liver disease. These patients originally had low T-cell percentage, high CD8+ cell percentage, and an enhanced antibody-dependent increase in lymphocyte cytotoxicity. All of these abnormal immune findings were normalized by a six-month course of silymarin. No significant changes were found after six months in the control group.³⁹

The second study looked at the hepatoprotective effect of silymarin in addition to its effects on normalizing immune function. Forty patients with alcoholic cirrhosis of the liver were given either silymarin, aminoimidazole-carboxamide-phosphate, or placebo in a one-month, double-blind clinical trial. In the treated groups, silymarin normalized elevated levels of AST, ALT, and total bilirubin, markedly reduced the high level of

GGT, decreased the percentage of OKT8+ cells, and suppressed lymphocytotoxicity.⁴⁰

Dosage/Toxicity

Silybum marianum is not water soluble and is typically administered as an encapsulated standardized extract (70-80% silymarin). In animals, silymarin has proven to be non-toxic when administered at high doses for short periods of time and long term dosage in rats has also failed to demonstrate any toxicity. Human studies have shown silymarin to be generally without side-effects. The typical adult dosage for silymarin is 240-900 mg/day in two or three divided doses. At higher doses (>1500 mg/day) silymarin may produce a laxative effect due to increased bile flow and secretion. Mild allergic reactions have also been noted, but neither of these side-effects was severe enough to discontinue treatment.⁴⁹⁻⁵¹

Picrorhiza kurroa

History/Traditional Use

Picrorhiza kurroa (fam. Scrophulariaceae) is a small perennial herb that grows in northwest India on the slopes of the Himalayas between 3000 and 5000 meters. It is an important herb in the traditional Ayurvedic system of medicine, and has been used to treat liver troubles and bronchial problems. Other traditional uses include dyspepsia (similar to gentian in its bitter quality), bilious fever, chronic dysentery, and scorpion sting. The roots and rhizomes are the part of the plant used medicinally.

Active Constituents

The most important active constituents of *Picrorhiza* are the iridoid glycoside picrosides I, II, III (Figure 3), and kutkoside, known collectively as kutkin.⁵² Many other active constituents have been identified, including nine cucurbitacin glycosides, apocynin, and drosin.⁵³

Clinical Indications

General Hepatoprotective: Picrorhiza has been shown to protect liver cells from a wide variety of insults including Amanita poisoning,^{54,55} carbon tetrachloride,⁵⁶⁻⁵⁸ galactosamine,⁵⁹⁻⁶¹ ethanol,⁶² aflatoxin B1,⁶³ acetaminophen,⁶⁴ thioacetamide,^{59,65} oxytetracycline,⁶⁶ and monocrotaline,⁶⁷ in both *in vitro* and *in vivo* experiments. When compared with silymarin, the hepatoprotective effect was found to be similar, or in many cases, superior to the effect of silymarin.^{58,61,64-66}


Picrorhiza has demonstrated significant hepatoprotective effects against Amanita mushroom poisoning in *in vivo* animal models.^{54,55} There are significantly fewer clinical studies on Picrorhiza than Silybum. One study, however, found the protective effect of Picrorhiza was comparable to silybin, and the curative efficacy of Picrorhiza appeared to be slightly superior.⁵⁵

Viral Hepatitis: Picrorhiza may be of value in the treatment of viral hepatitis. In an Indian study on 32 patients diagnosed with acute viral hepatitis (HBsAg negative), 15 patients in the treatment group were given Picrorhiza root powder, 375 mg three times daily for two weeks. Liver enzymes (AST and ALT) and bilirubin were significantly lower in the treatment group. The number of days required for total serum bilirubin to drop to an average value of 2.5 milligrams percent was 75.9 days in the placebo group, as compared to 27.4 days in the treatment group.⁶⁸

Another study investigated *in vitro* anti-hepatitis B virus surface antigen

(anti-HBs)-like activity. HbsAg-positive serum samples obtained from hepatitis B virus (HBV)-associated acute and chronic liver diseases and healthy HBsAg carriers were used to evaluate the anti-HBs-like activity of Picrorhiza and other compounds. Promising anti-HBsAg activity was noted with Picrorhiza. Picrorhiza also inhibited purified HBV antigens prepared from healthy HBsAg carriers.⁶⁹

Figure 3. Picroside I



Mechanisms of Action

Antioxidant: The mechanism by which Picrorhiza affords protection to the liver is not completely understood, but several possibilities have come to light. Like silymarin, Picrorhiza does possess significant antioxidant activity *in vitro* which may contribute to the hepatoprotective effect by reducing lipid peroxidation and free radical damage.⁷⁰ Chander et al found that Picrorhiza and its main constituents, picroside-I and kutkoside, inhibited the non-enzymatic generation of O₂⁻ anions in a phenazine methosulphate NADH system, inhibited oxidative malonaldehyde generation by both the ascorbate-Fe²⁺ and NADPH-ADP-Fe²⁺ systems, and scavenged superoxide (O₂⁻) anions generated in a xanthine-xanthine oxidase system. In other words, Picrorhiza demonstrated antioxidant activity similar to that of superoxide dismutase, metal-ion chelators, and xanthine oxidase inhibitors.⁷⁰

Glutathione is vital to maintaining a variety of intracellular functions, including detoxification, antioxidation, tertiary protein configuration, and redox balance.⁷¹ Picrorhiza was found to restore depleted glutathione levels in African desert rats infected with

Plasmodium berghei (malaria). Several enzymes associated with glutathione function were also restored, including glutathione-S-transferase, glutathione reductase, and glutathione peroxidase.⁷² Generation of lipid peroxides in African desert rats infected with *Plasmodium berghei* was significantly reduced by Picrorhiza at the oral dose of 6 mg/kg for two weeks, revealing Picrorhiza also possesses anti-lipid peroxidative effects.⁷³

Stimulation of Liver Regeneration: Like silymarin, Picrorhiza may have an effect on liver regeneration. A 1992 study demonstrated stimulation of nucleic acid and protein synthesis in rat liver with oral administration of Picrorhiza. The authors stated the results were comparable to silymarin.⁷⁴

Anti-inflammatory: Another factor in the hepatoprotection of Picrorhiza may be its anti-inflammatory effects. Picrorhiza extracts were found to have an inhibitory effect on such pro-inflammatory cells as neutrophils, macrophages, and mast cells.⁷⁵ The authors suggested Picrorhiza extract inhibited membrane-mediated activation of these cells (inhibited 8-adrenergic receptors).^{76,77} The researchers found no effect of the Picrorhiza extract on prostaglandin production.⁷⁵

Picrorhiza contains apocynin, a catechol, as one of its minor constituents. Apocynin has been found to exhibit powerful anti-inflammatory effects on a variety of inflammatory models. Apocynin was found to inhibit neutrophil oxidative burst *in vitro* without affecting beneficial activities such as chemotaxis, phagocytosis, and intracellular killing of bacteria.^{78,79}

In *in vivo* animal models, apocynin inhibited lipopolysaccharide-induced emphysema in hamsters.⁸⁰ Apocynin prevented the formation of ulcerative lesions in rats injected intracutaneously with Freund's complete adjuvant,⁸¹ and reduced swelling in collagen-immunized rats. No effects on humoral and cellular immunity were observed

after treatment with apocynin.^{82,83} What is remarkable about the last study is the effective daily dose of apocynin was only 0.024 mg/kg. Such a dose is readily achieved from normal use of Picrorhiza root instead of the concentrated apocynin extract.^{82,83}

Choleretic: Several hepatotoxins, including paracetamol and ethynylestradiol, have a cholestatic effect on the production of bile. Picrorhiza has been shown to reverse acetaminophen and ethynylestradiol-induced cholestasis, maintaining both bile volume and flow. Silymarin was tested simultaneously for comparison. Picrorhiza was found to be a more potent choleretic and anticholestatic agent than silymarin.⁸⁴

Dosage/Toxicity

Picrorhiza is poorly soluble in water and so is usually not taken as a tea. It is soluble in ethanol and so can be taken in tincture form (very bitter), but is usually administered as an encapsulated standardized extract (4% kutkin).⁸⁵ The usual adult dosage is 400 to 1500 mg/day, although daily doses as high as 3.5 g/day have been recommended for fevers.⁸⁶

Picrorhiza use is widespread in India and no major adverse reactions have been reported. The oral LD50 of kutkin is greater than 2600 mg/kg in rats.⁸⁷ The LD50 of picroside and kutkoside is greater than 1000 mg/kg in rats.⁸⁷ By comparison, the maximum dose achievable with oral ingestion of Picrorhiza root is about 3-6 mg/kg.

Conclusion

Clinical research has confirmed the efficacy and safety of several botanicals for the treatment of liver disease. Both *Silybum marianum* and *Picrorhiza kurroa* have a long tradition of use as hepatoprotective herbs. Scientific research has elucidated many of the mechanisms by which these two herbs provide their hepatoprotective effect. As a result these plants are now being more widely used in the

treatment of liver diseases such as toxic hepatitis, fatty liver, cirrhosis, ischemic injury, radiation toxicity, and viral hepatitis.

References

1. Pliny the Elder, *Historia Naturalis* 77 A.D.
2. Culpeper N. *A Physical Directory: or a Translation of the Dispensatory made by the College of Physicians of London*. London, England: Peter Cole; 1650.
3. Morazzoni P, Montalbetti A, Malandrino S. Comparative pharmacokinetics of silipide and silymarin in rats. *Eur J Drug Metab Pharmacokinet* 1993;18:289-297.
4. Schandalik R, Gatti G, Perucca E, et al. Pharmacokinetics of silybin in bile following administration of silipide and silymarin in cholecystectomy patients. *Arzneimittelforschung* 1992;42:964-968.
5. Weyhenmeyer R, Mascher H, Birkmayer J, et al. Study on dose-linearity of the pharmacokinetics of silibinin diastereomers using a new stereospecific assay. *Int J Clin Pharmacol Ther Toxicol* 1992;30:134-138.
6. Vogel G, Tuchweber B, Trost W. Protection by silibinin against *Amanita phalloides* intoxication in beagles. *Toxicol Appl Pharmacol* 1984;73:355-362.
7. Desplaces A, Choppin J, Vogel G. The effects of silymarin on experimental phalloidine poisoning. *Arzneimittelforschung* 1975;25:89-96.
8. Hruby K, Csomos G, Fuhrmann M, Thaler H. Chemotherapy of *Amanita phalloides* poisoning with intravenous silibinin. *Hum Toxicol* 1983;2:183-195.
9. Sabeel AI, Kurkus J, Lindholm T. Intensive hemodialysis and hemoperfusion treatment of *Amanita* mushroom poisoning. *Mycopathologia* 1995;131:107-114.
10. Carducci R, Armellino NIF, Volpe C, et al. Silibinin and acute poisoning with *Amanita phalloides*. *Minerva Anestesiol* 1996;62:187-193. [Article in Italian]
11. Rambousek V, Janda I, Sikut M, et al. Severe *Amanita phalloides* poisoning in a 7-year-old girl. *Cesk Pediatr* 1993;48:332-333. [Article in Czech]
12. Salmi HA, Sarna S. Effect of silymarin on chemical, functional, and morphological alterations of the liver; A double blind controlled study. *Scand J Gastroenterol* 1982;17:517-521.
13. Buzzelli G, Moscarella S, Giusti A, et al. A pilot study on the liver protective effect of silybin-phosphatidylcholine complex (1dB 1016) in chronic active hepatitis. *Int J Clin Pharmacol Ther Toxicol* 1993;31:456-460.
14. Feher I, Deak G, Muzes G. Liver-protective action of silymarin therapy in chronic alcoholic liver diseases. *Orv Hetil* 1989;130:2723-2727. [Article in Hungarian]
15. Ferenci P, Dragosics B, Dittrich H, et al. Randomized controlled trial of silymarin treatment in patients with cirrhosis of the liver. *J Hepatol* 1989;9:105-113.
16. Trinchet IC, Coste T, Levy VG. Treatment of alcoholic hepatitis with silymarin. A double-blind comparative study in 116 patients. *Gastroenterol Clin Biol* 1989;13:120-124. [Article in French]
17. Varga M, Buris L, Fodor M. Ethanol elimination in man under influence of hepatoprotective silibinin. *Blutalkohol* 1991;28:405-408.
18. Muriel P, Mourelle M. Prevention by silymarin of membrane alterations in acute CCl₄ liver damage. *J Appl Toxicol* 1990;10:275-279.
19. Bosisio E, Benelli C, Pirola O, et al. Effect of the flavanolignans of *Silybum marianum* L. on lipid peroxidation in rat liver microsomes and freshly isolated hepatocytes. *Pharmacol Res* 1992;25:147-154.
20. Muriel P, Garciapina T, Perez-Alvarez V, et al. Silymarin protects against paracetamol-induced lipid peroxidation and liver damage. *J Appl Toxicol* 1992;12:439-442.
21. Halim AB, el-Ahmady O, Hassab-Allah S, et al. Biochemical effect of antioxidants on lipids and liver function in experimentally-induced liver damage. *Ann Clin Biochem* 1997;34:656-663.
22. Chrunghoo VJ, Singh K, Singh I. Silymarin mediated differential modulation of toxicity induced by carbon tetrachloride, paracetamol and D-galactosamine in freshly isolated rat hepatocytes. *Indian J Exp Biol* 1997;35:611-617.

23. Campos R, Garrido A, Guerra R, et al. Silybin dihemisuccinate protects against glutathione depletion and lipid peroxidation induced by acetaminophen on rat liver. *Planta Med* 1989;55:417-419.
24. Wu CG, Chamuleau RA, Bosch KS. Protective effect of silymarin on rat liver injury induced by ischemia. *Virchows Arch B Cell Pathol Incl Mol Pathol* 1993;64:259-263.
25. Kropacova K, Misurova E, Hakova H. Protective and therapeutic effect of silymarin on the development of latent liver damage. *Radiats Biol Radioecol* 1998;38:411-415.
26. Pietrangelo A, Borella F, Casalgrandi G. Antioxidant activity of silybin *in vivo* during long-term iron overload in rats. *Gastroenterology* 1995;109:1941-1949.
27. McPartland JM. Viral hepatitis treated with *Phyllanthus amarus* and milk thistle (*Silybum marianum*): A case report. *Complementary Medicine International* 1996;March/April:40-42.
28. Basaga H, Poli G, Tekkaya C, et al. Free radical scavenging and antioxidative properties of 'silibin' complexes on microsomal lipid peroxidation. *Cell Biochem Funct* 1997;15:27-33.
29. Rui YC. Advances in pharmacological studies of silymarin. *Mem Inst Oswaldo Cruz* 1991;S2:79-85.
30. Baer-Dubowska W, Szaefer H, Krajka-Kuzniak V. Inhibition of murine hepatic cytochrome P450 activities by natural and synthetic phenolic compounds. *Xenobiotica* 1998;28:735-743.
31. Miguez MP, Anundi I, Sainz-Pardo LA. Hepatoprotective mechanism of silymarin: no evidence for involvement of cytochrome P450 2E1. *Chem Biol Interact* 1994;91:51-63.
32. Kim DH, Jin YH, Park JB, Kobashi K. Silymarin and its components are inhibitors of beta-glucuronidase. *Biol Pharm Bull* 1994;17:443-445.
33. Cabrera C. "Milk Thistle: A clinician's report." *Medical Herbalism* 1996;6:1-5.
34. Fiebrich F, Koch H. Silymarin, an inhibitor of lipoxygenase. *Experientia* 1979;35:1548-1560.
35. Sonnenbichler J, Goldberg M, Hane L, et al. Stimulatory effect of silibinin on the DNA synthesis in partially hepatectomized rat livers: non-response in hepatoma and other malignant cell lines. *Biochem Pharmacol* 1986;35:538-541.
36. Schopen RD, Lange OK, Panne C. Searching for a new therapeutic principle. Experience with hepatic therapeutic agent legalon. *Medical Welt* 1969;20:888-893.
37. Zi X, Mukhtar H, Agarwal R. Novel cancer chemopreventive effects of a flavonoid antioxidant silymarin: inhibition of mRNA expression of an endogenous tumor promoter TNF-alpha. *Biochem Biophys Res Commun* 1997;239:334-339.
38. Fantozzi R, Brunelleschi S, Rubino A, et al. FMLP-activated neutrophils evoke histamine release from mast cells. *Agents Actions* 1986;18:155-158.
39. Deak G, Muzes G, Lang I. Immunomodulator effect of silymarin therapy in chronic alcoholic liver diseases. *Orv Hetil* 1990;131:1291-1292, 1295-1296. [Article in Hungarian]
40. Lang I, Nekam K, Gonzalez-Cabello R. Hepatoprotective and immunological effects of antioxidant drugs. *Tokai J Exp Clin Med* 1990;15:123-127.
41. Sonnenbichler J, Zetl I. Biochemical effects of the flavolignane silibinin on RNA, protein and DNA synthesis in rat livers. In: Cody V, Middleton E, and Harbourne JB, ed. *Plant Flavonoids in Biology and Medicine: Biochemical, Pharmacological, and Structure-Activity relationships*. New York: Alan R. List, Inc.; 1986:319-331.
42. Dehmloew C, Murawski N, de Groot H, et al. Scavenging of reactive oxygen species and inhibition of arachidonic acid metabolism by silibinin in human cells. *Life Sci* 1996;58:1591-1600.
43. Dehmloew C, Erhard J, de Groot H. Inhibition of Kupffer cell functions as an explanation for the hepatoprotective properties of silibinin. *Hepatology* 1996;23:749-754.
44. Fuchs EC, Weyhenmeyer R, Weiner OH, et al. Effects of silibinin and of a synthetic analogue on isolated rat hepatic stellate cells and myofibroblasts. *Arzneimittelforschung* 1997;47:1383-1387.
45. Boigk G, Stroedter L, Herbst H. Silymarin retards collagen accumulation in early and advanced biliary fibrosis secondary to complete bile duct obliteration in rats. *Hepatology* 1997;26:643-649.
46. Favari L, Perez-Alvarez V. Comparative effects of colchicine and silymarin on CCl₄-chronic liver damage in rats. *Arch Med Res* 1997;28:11-17.

47. De La Puerta R, Martinez E, Bravo L. Effect of silymarin on different acute inflammation models and on leukocyte migration. *J Pharm Pharmacol* 1996;48:968-970.
48. Amdur MO, Doull J, Klaassen CD. *Casarett and Doull's Toxicology: The Basic Science of Poisons*, 4th ed. New York, NY: McGraw-Hill; 1991.
49. Awang D. No title available. *Can Pharm J* 1993;October:403-404.
50. Romyantseva A. No title available. *Vrach Delo* 1991;5:15-19.
51. Brown D. *Drug Store News for the Pharmacist* 1994;4:58,60.
52. Weinges K, Kloss P, Henkels WD. Natural products from medicinal plants. XVII. Picroside-II, a new 6-vanilloyl-catapol from *Picrorhiza kurroa* Royle and Benth. *Justus Liebigs Ann Chem* 1972;759:173-182. [Article in German]
53. Stuppner H, Wagner H. New cucurbitacin glycosides from *Picrorhiza kurroa*. *Planta Med* 1989;55:559-563.
54. Dwivedi Y, Rastogi R, Garg NK, et al. Effects of picroliv, the active principle of *Picrorhiza kurroa*, on biochemical changes in rat liver poisoned by *Amanita phalloides*. *Chung Kuo Yao Li Hsueh Pao* 1992;13:197-200.
55. Floersheim GL, Bieri A, Koenig R, Pletscher A. Protection against *Amanita phalloides* by the iridoid glycoside mixture of *Picrorhiza kurroa* (kutkin). *Agents Actions* 1990;29:386-387.
56. Santra A, Das S, Maity A, et al. Prevention of carbon tetrachloride-induced hepatic injury in mice by *Picrorhiza kurroa*. *Indian J Gastroenterol* 1998;17:6-9.
57. Dwivedi Y, Rastogi R, Chander R, et al. Hepatoprotective activity of picroliv against carbon tetrachloride-induced liver damage in rats. *Indian J Med Res* 1990;92:195-200.
58. Saraswat B, Visen PK, Patnaik GK, et al. Anticholestatic effect of picroliv, active hepatoprotective principle of *Picrorhiza kurroa*, against carbon tetrachloride induced cholestasis. *Indian J Exp Biol* 1993;31:316-318.
59. Dwivedi Y, Rastogi R, Garg NK, et al. Perfusion with picroliv reverses biochemical changes induced in livers of rats toxicated with galactosamine or thioacetamide. *Planta Med* 1993;59:418-420.
60. Dwivedi Y, Rastogi R, Garg NK, et al. Picroliv and its components kutkoside and picroside I protect liver against galactosamine-induced damage in rats. *Pharmacol Toxicol* 1992;71:383-387.
61. Visen PK, Shukla B, Patnaik GK, et al. Prevention of galactosamine-induced hepatic damage by picroliv: study on bile flow and isolated hepatocytes (*ex vivo*). *Planta Med* 1993;59:37-41.
62. Rastogi R, Saksena S, Garg NK, et al. Picroliv protects against alcohol-induced chronic hepatotoxicity in rats. *Planta Med* 1996;62:283-285.
63. Dwivedi Y, Rastogi R, Mehrotra R, et al. Picroliv protects against aflatoxin B1 acute hepatotoxicity in rats. *Pharmacol Res* 1993;27:189-199.
64. Singh V, Visen PK, Patnaik GK, et al. Effect of picroliv on low density lipoprotein receptor binding of rat hepatocytes in hepatic damage induced by paracetamol. *Indian J Biochem Biophys* 1992;29:428-432.
65. Dwivedi Y, Rastogi R, Sharma SK, et al. Picroliv affords protection against thioacetamide-induced hepatic damage in rats. *Planta Med* 1991;57:25-28.
66. Saraswat B, Visen PK, Patnaik GK, et al. Protective effect of picroliv, active constituent of *Picrorhiza kurroa*, against oxytetracycline induced hepatic damage. *Indian J Exp Biol* 1997;35:1302-1305.
67. Dwivedi Y, Rastogi R, Sharma SK, et al. Picroliv protects against monocrotaline-induced hepatic damage in rats. *Pharmacol Res* 1991;23:399-407.
68. Vaidya AB, Antarkar DS, Doshi IC, et al. *Picrorhiza kurroa* (Kutaki) Royle ex Benth as a hepatoprotective agent—experimental and clinical studies. *J Postgrad Med* 1996;42:105-108.
69. Mehrotra R, Rawat S, Kulshreshtha DK, et al. *In vitro* studies on the effect of certain natural products against hepatitis B virus. *Indian J Med Res* 1990;92:133-138.
70. Chander R, Kapoor NK, Dhawan BN. Picroliv, picroside-I and kutkoside from *Picrorhiza kurroa* are scavengers of superoxide anions. *Biochem Pharmacol* 1992;44:180-183.
71. Kidd PM. Glutathione: Systemic protection against oxidative and free radical damage. *Altern Med Rev* 1997;2:155-176.

72. Chander R, Kapoor NK, Dhawan BN. Effect of picroliv on glutathione metabolism in liver and brain of *Mastomys natalensis* infected with *Plasmodium berghei*. *Indian J Exp Biol* 1992;30:711-714.
73. Chander R, Singh K, Visen PK, et al. Picroliv prevents oxidation in serum lipoprotein lipids of *Mastomys coucha* infected with *Plasmodium berghei*. *Indian J Exp Biol* 1998;36:371-374.
74. Singh V, Kapoor NK, Dhawan BN. Effect of picroliv on protein and nucleic acid synthesis. *Indian J Exp Biol* 1992;30:68-69.
75. Pandey BL, Das PK. Immunopharmacological studies on *Picrorhiza kurroa* Royle-ex-Benth. Part IV: Cellular mechanisms of anti-inflammatory action. *Indian J Physiol Pharmacol* 1989;33:28-30.
76. Pandey BL, Das PK. Immunopharmacological studies on *Picrorhiza kurroa* Royle-Ex-Benth. Part V: Anti-inflammatory action: relation with cell types involved in inflammation. *Indian J Physiol Pharmacol* 1988;32:289-292.
77. Pandey BL, Das PK. Immunopharmacological studies on *Picrorhiza kurroa* Royle-ex-Benth. Part III: Adrenergic mechanisms of anti-inflammatory action. *Indian J Physiol Pharmacol* 1988;32:120-125.
78. Simons JM, 't Hart BA, Ip Vai Ching TR, et al. Metabolic activation of natural phenols into selective oxidative burst agonists by activated human neutrophils. *Free Radic Biol Med* 1990;8:251-258.
79. Stolk J, Hiltermann TJ, Dijkman JH, et al. Characteristics of the inhibition of NADPH oxidase activation in neutrophils by apocynin, a methoxy-substituted catechol. *Am J Respir Cell Mol Biol* 1994;11:95-102.
80. Stolk I, Rossie W, Dijkman JH. Apocynin improves the efficacy of secretory leukocyte protease inhibitor in experimental emphysema. *Am J Respir Crit Care Med* 1994;150:1628-1631.
81. 't Hart BA, Elferink IG, Nibbering PH. Effect of apocynin on the induction of ulcerative lesions in rat skin injected with tubercle bacteria. *Int J Immunopharmacol* 1992;14:953-961.
82. 't Hart BA, Bakker NP, Labadie RP, et al. The newly developed neutrophil oxidative burst antagonist apocynin inhibits joint-swelling in rat collagen arthritis. *Agents Actions Suppl* 1991;32:179-184.
83. 't Hart BA, Simons IM, Knaan-Shanzer S, et al. Antiarthritic activity of the newly developed neutrophil oxidative burst antagonist apocynin. *Free Radic Biol Med* 1990;9:127-131.
84. Shukla B, Visen PK, Patnaik GK, et al. Choleric effect of picroliv, the hepatoprotective principle of *Picrorhiza kurroa*. *Planta Med* 1991;57:29-33.
85. Chopra RN. *Indigenous Drugs of India*. 2nd ed. Reprint. Calcutta, New Delhi: Academic Publishers; 1982.
86. Kapoor LD. *CRC Handbook on Ayurvedic Medicinal Plants*. Boca Raton, Florida: CRC Press;1990.
87. Annual Report, Regional Research Laboratory, Council for Scientific and Industrial Research, India. 1989-1990.